Migraine Resource Network is a comprehensive educational initiative for clinicians seeking current and emerging information on migraine headache. Our mission is to provide ongoing medical education that embodies evidence-based scientific data, current treatment strategies, and the insightful knowledge of expert faculty. Our goal is to support your ongoing dedication to optimizing treatment outcomes for your patients.

Skip to content

Migraine Resource Network

You are here: Home Continuing Ed Migraine 101 (Accredited)

You need to be logged in to continue.
Please Log In or Register.

You can no longer receive credit for taking this course

Migraine Headache in Pregnancy

Release Date: March 31, 2009
Expiration Date: March 31, 2010


Program Overview

Migraine can first occur, become worse, or abate in women who are pregnant. Sources suggest that each of these occurrences may be due to fluctuations in estrogen and other sex hormones. Benefits of pharmacotherapies must be weighed against risks prior to prescribing or administration of a drug at any time, but especially during pregnancy in consideration of undesirable teterogenic effects.

This case study highlights appropriate medical management of a pregnant woman with migraine based on the evidence in the literature, not guidelines, as none currently exists. Dr. Lavigne also discusses the case at length, and provides insight about use of acute and prophylactic medications typically prescribed for migraine in women when they are not pregnant, and how their use is contraindicated, adjusted or discontinued during pregnancy in the female migraineur. A set of companion slides is available for support of the core messages of the case study.

Target Audience

This activity is designed for physicians, pharmacists and other allied health care professionals involved in the management of migraine.

Learning Objectives

After completion of this educational activity, participants will be able to:

  • Understand that migraine is a common condition in women who are pregnant, many of whom will seek medical help in an emergency department.
  • Recognize the benefits and risks involved with use of pharmacologic therapies for migraine in women who are pregnant to provide optimal therapeutic decision-making.
  • Differentiate use of acute therapy versus prophylactic therapy for migraine in women who are pregnant to benefit patient outcomes.

General Information

This activity is eligible for credit through March 31, 2010. After this date, this activity will expire and no further credit will be awarded.

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in this activity. All participants must complete the Activity Evaluation Form. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. Certificates may be printed immediately after successfully completing the online self-assessment and evaluation.

Faculty Biography

Catherine M. Lavigne, MD
Associate Neurologist
Brigham and Women's Hospital/Faulkner Hospital
Boston, Massachusetts

Dr. Catherine Lavigne received her medical degree from the University of Rochester School of Medicine and Dentistry, Rochester, New York. She continued her postgraduate studies as an intern in medicine at Rochester General Hospital, and was a resident and chief resident in neurology at Massachusetts General Hospital/Brigham & Women's Hospital. Dr. Lavigne was also a fellow in headache neurology at Brigham and Women's Hospital/Faulkner Hospital, Boston, where she is currently an associate neurologist.

Dr. Lavigne is a member of the American Headache Society and assistant editor of Headache.


Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of MediCom Worldwide, Inc. and Medical Learning Solutions. MediCom Worldwide, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .5 contact hour(s) of Continuing Education Credit. Universal Activity Number: 827-000-09-226-H01-P Knowledge-based CPE activity.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME), ACPE and California Board of Nursing, MediCom Worldwide, Inc. requires that all program planners, faculty, and providers who are in a position to control the content of a CE activity are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity. Accordingly the following disclosures were made.

Faculty Disclosure

Dr. Catherine Lavigne has disclosed that she has no significant relationships with the grantor Endo Pharmaceuticals or any other commercial company whose products and services may be related to her presentation.

Planner and Provider Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, executive director; Norma Jean Talley, manager, professional education; and Ruth Widmer, medical editor, have nothing to disclose.

Off-Label/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Lavigne indicated that her presentation would include the discussion of unlabeled uses of sumatriptan s.c. that are not approved by the FDA for certain uses in the United States. Dr. Lavigne indicated that her presentation would not include the discussion of investigational products that have not been approved by the FDA for any use in the United States.

Conflict of Interest Resolution

To resolve identified conflicts of interest, the educational content was fully peer reviewed by members of the MediCom Content Review Committee. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

This activity is supported by an educational grant from Endo Pharmaceuticals.

©2009 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067. No portion of this material may be copied or duplicated without written permission of MediCom.

You need to be logged in to continue.
Please Log In or Register.